Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892722 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT01892722: Active Phase 3 study of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
NCT01892722 is a Phase 3 study of Multiple Sclerosis that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 240 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01892722, a Phase 3 study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Primary Outcome
Frequency of relapses assessed by the annualized relapse rate (ARR). The ARR is defined as the average number of confirmed relapses per year (total number of confirmed relapses divided by the total days in the study multiplied by 365.25).
Conditions Studied
Interventions
- DRUG Fingolimod
- DRUG Placebo capsule
- DRUG Interferon beta-1a
- DRUG Placebo i.m. injection
Study Locations (20)
Other
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Goiânia
- Novartis Investigative Site - Sofia
- Novartis Investigative Site - Osijek
California
- Childrens Hospital Los Angeles - Los Angeles
- UCSF - San Francisco
Florida
- University of Miami - Miami
- AMO Corporation - Tallahassee
Alabama
- UAB Childrens Hospital Harbor Center Neurology Dept - Birmingham
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Wayne State University - Detroit
New Jersey
- Robert Wood Johnson Medical School - New Brunswick
Pennsylvania
- Childrens Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2013-07-26 |
| Est. Completion | 2030-02-18 |
| Phase | Phase 3 |
What the registry record for NCT01892722 still lists
NCT01892722 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 4 interventions - of which Fingolimod is the first listed.
NCT01892722 names 20 study sites across 15 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01892722 about?
NCT01892722 is a clinical study titled "Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis". To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
What is the current status of trial NCT01892722?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2013-07-26. Estimated completion is 2030-02-18.
What conditions does trial NCT01892722 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01892722?
The interventions under investigation include: Fingolimod (DRUG), Placebo capsule (DRUG), Interferon beta-1a (DRUG), Placebo i.m. injection (DRUG).
Who is sponsoring clinical trial NCT01892722?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01892722 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01892722's enrollment target sits among peer trials
240 71st of 315 higher than 245 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI